Payment overview · 2025
General Payments
$274.45
12 reported records · 7 companies
Healthcare provider profile · identity verified
Mario Masserano, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DELRAY BEACH, FL · NPI 1154416972
Verified facts
What the public records show
CMS Open Payments records show Mario Masserano, M.D. received $274.45 in general payments during 2025 across 12 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xifaxan.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $104.84 | 38.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.35 | 18.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.21 | 11.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $28.22 | 10.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.50 | 8.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.48 | 7.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.85 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.45 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $104.84 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 96 |
| Losartan Potassium | Losartan Potassium | 232 | 68 |
| Alprazolam | Alprazolam | 219 | 51 |
| Potassium Chloride | Potassium Chloride | 205 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 52 |
| Eliquis | Apixaban | 173 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 43 |
| Gabapentin | Gabapentin | 152 | 41 |
| Montelukast Sodium | Montelukast Sodium | 148 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 38 |
| Metformin Hcl | Metformin Hcl | 119 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 27 |
| Furosemide | Furosemide | 101 | 41 |
| Azithromycin | Azithromycin | 96 | 75 |
| Lisinopril | Lisinopril | 96 | 31 |
| Tramadol Hcl | Tramadol Hcl | 91 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Simvastatin | Simvastatin | 89 | 29 |
| Omeprazole | Omeprazole | 86 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 66 |
| Donepezil Hcl | Donepezil Hcl | 83 | 21 |
| Allopurinol | Allopurinol | 78 | 32 |
| Mirtazapine | Mirtazapine | 77 | 17 |
| Memantine Hcl | Memantine Hcl | 73 | 17 |
| Finasteride | Finasteride | 67 | 15 |
| Atenolol | Atenolol | 65 | 19 |
| Clonazepam | Clonazepam | 64 | 12 |
| Xarelto | Rivaroxaban | 62 | 15 |
| Lorazepam | Lorazepam | 59 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 13 |
| Methylprednisolone | Methylprednisolone | 54 | 42 |
| Trazodone Hcl | Trazodone Hcl | 54 | 21 |
| Meloxicam | Meloxicam | 52 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Temazepam | Temazepam | 50 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 20 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Sertraline Hcl | Sertraline Hcl | 44 | 21 |
| Famotidine | Famotidine | 43 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 26 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | 16 |
| Valsartan | Valsartan | 37 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 18 |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 16 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 11 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 12 |
| Mupirocin | Mupirocin | 27 | 20 |
| Nystatin | Nystatin | 27 | 17 |
| Methocarbamol | Methocarbamol | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Cephalexin | Cephalexin | 23 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Carvedilol | Carvedilol | 17 | 11 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.45 · 12 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Cologuard Collection Kit, Leqembi, MOUNJARO, REXULTI, The Cologuard Plus Collection Kit, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xifaxan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Salix Pharmaceuticals, a division of Bausch Health US, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error